Mylan, Pfizer settle patent suit on generic Detrol LA

Fri Sep 7, 2012 5:35pm IST

Stocks

   

(Reuters) - Mylan Inc said it settled with Pfizer Inc a lawsuit that accused it of infringing patents on overactive bladder drug Detrol LA.

Mylan can start selling its generic versions of Pfizer's drug from January 1, 2014, or earlier under some limited circumstances, but not after March 1, 2014, if the U.S. Food and Drug Administration approves.

Terms of the settlement are subject to review by the Federal Trade Commission and the U.S. Department of Justice, and other details are confidential, Mylan said.

The settlement with Mylan comes days after Pfizer resolved a similar dispute with Impax Laboratories Inc late last month.

(Reporting by Zeba Siddiqui in Bangalore; Editing by Akshay Lodaya)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Modi's U.S. Trip

REUTERS SHOWCASE

Shortage of Coal

Shortage of Coal

Coal import rush leads to port congestion  Full Article 

Modi's U.S. Visit

Modi's U.S. Visit

Modi to observe strict fast during maiden trip to U.S.  Full Article 

Mars Mission

Mars Mission

India's Mars mission a step closer to success with engine test  Full Article 

Bumper Sales

Bumper Sales

Apple sells more than 10 mln new iPhones in first three days  Full Article 

Dubai Housing

Dubai Housing

Dubai housing costs soar to Manhattan peaks, forcing moves to outskirts  Full Article 

Whistleblower Award

Whistleblower Award

U.S. SEC to pay $30 million-plus in largest whistleblower award  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage